Author

R. Gajardo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

C. Romero· 5 shared J.-M. Diez· 4 shared B. Clotet· 1 shared B. Trinite· 1 shared D. Casals· 1 shared E. Pradenas· 1 shared I. Sola· 1 shared J. Blanco· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

C. Romero

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Seasonal IVIG contains high infectivity neutralizing and hemagglutination inhibition activity against seasonal flu virus strains selected for vaccines (2020-22)

J.-M. Diez, D. Casals, C. Romero, R. Gajardo

The paper tests IVIG for neutralizing and hemagglutination inhibition against seasonal flu strains and finds potent activity, suggesting potential as an adjunct therapy for influenza.

bioRxiv · Jan 31, 2022 · PreprintImmunology

Anti-SARS-CoV-2 hyperimmune immunoglobulin provides potent and robust neutralization capacity and antibody-dependent cellular cytotoxicity and phagocytosis induction through N and S proteins

J.-M. Diez, C. Romero, M. Cruz, P. Vandeberg, W. K. Merritt, E. Pradenas, B. Trinite, J. Blanco, B. Clotet, T. Willis, R. Gajardo

This study evaluates the neutralization and antibody-dependent cellular effects of anti-SARS-CoV-2 hyperimmune immunoglobulin against multiple SARS-CoV-2 isolates and variants.

The Journal of Infectious Diseases · Oct 25, 2021Peer-reviewedImmunology

Effective presence of antibodies against common human coronavirus in IgG immunoglobulin medicinal products.

J.-M. Diez, C. Romero, R. Gajardo

The paper tests IgG immunoglobulin products from different geographic regions for antibodies against common human coronaviruses and finds similar anti-HCoV activity across products, with highest activity against HCoV-229E.

bioRxiv · Jul 23, 2021Immunology

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins

J. M. Diez, C. Romero, J. Vergara Alert, M. Bello Perez, J. Rodon, J. M. Honrubia, J. Segales, I. Sola, L. Enjuanes, R. Gajardo

This study shows that currently available IVIG products neutralize SARS-CoV-2 and SARS-CoV in cell cultures but not MERS-CoV.

bioRxiv · Jun 19, 2020Immunology

Currently available intravenous immunoglobulin (Gamunex(C)-C and Flebogamma(C) DIF) contains antibodies reacting against SARS-CoV-2 antigens

J.-M. Diez, C. Romero, R. Gajardo

This study assesses IVIG products for antibodies against SARS-CoV-2 antigens, finding cross-reactivity with related coronaviruses.

bioRxiv · Apr 7, 2020Immunology